AMPA receptor flip\/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1996<\/year><\/dates><electronic-resource-num>10.1523\/jneurosci.16-21-06634.1996<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.jneurosci.org\/content\/jneuro\/16\/21\/6634.full.pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>2<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1991<\/year><\/dates><electronic-resource-num>10.1073\/pnas.88.23.10936<\/electronic-resource-num><urls><related-urls><url>https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.88.23.10936<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>3<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2012<\/year><\/dates><electronic-resource-num>10.1111\/j.1755-5949.2010.00244.x<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/6493642<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>4<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Aniracetam does not alter cognitive and affective behavior in adult C57BL\/6J mice.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.1371\/journal.pone.0104443<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC4123976?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>5<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Oral aniracetam treatment in C57BL\/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2017<\/year><\/dates><electronic-resource-num>10.12688\/f1000research.11023.3<\/electronic-resource-num><urls><related-urls><url>https:\/\/f1000research.com\/articles\/6-1452\/v3\/pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>6<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Spectrofluorimetric study on fluorescence quenching of tyrosine and l-tryptophan by the aniracetam cognition enhancer drug: quenching mechanism using Stern-Volmer and double-log plots.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2020<\/year><\/dates><electronic-resource-num>10.1002\/bio.3778<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>7<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Aniracetam does not improve working memory in neurologically healthy pigeons.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2019<\/year><\/dates><electronic-resource-num>10.1371\/journal.pone.0215612<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC6474613?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>8<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Designing a Formulation of the Nootropic Drug Aniracetam Using 2-Hydroxypropyl-\u03b2-Cyclodextrin Suitable for Parenteral Administration.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2018<\/year><\/dates><electronic-resource-num>10.3390\/pharmaceutics10040240<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC6320825?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>9<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1992<\/year><\/dates><electronic-resource-num>10.1002\/hipo.450020107<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>10<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Content determination of aniracetam in aniracetam inclusion complex by HPLC.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2009<\/year><\/dates><electronic-resource-num>10.1080\/10731190902908387<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10731190902908387?download=true<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>11<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Aniracetam attenuates H2O2-induced deficiency of neuron viability, mitochondria potential and hippocampal long-term potentiation of mice in vitro.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2006<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>12<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2003<\/year><\/dates><electronic-resource-num>10.1124\/mol.64.2.269<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>13<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>The hypoxia model in human psychopharmacology: neurophysiological and psychometric studies with aniracetam i.v.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1984<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>14<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Nakamura K<\/author><\/authors><\/contributors><titles><title>Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.<\/title><secondary-title>CNS drug reviews<\/secondary-title><\/titles><dates><year>2002<\/year><\/dates><electronic-resource-num>10.1111\/j.1527-3458.2002.tb00216.x<\/electronic-resource-num><urls><related-urls><url>https:\/\/onlinelibrary.wiley.com\/doi\/pdfdirect\/10.1111\/j.1527-3458.2002.tb00216.x<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>15<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>[3H]aniracetam binds to specific recognition sites in brain membranes.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1995<\/year><\/dates><electronic-resource-num>10.1046\/j.1471-4159.1995.65020912.x<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>16<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Development and validation of a liquid chromatographic method for the simultaneous determination of aniracetam and its related substances in the bulk drug and a tablet formulation.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2011<\/year><\/dates><electronic-resource-num>10.1016\/j.jpba.2011.06.005<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>17<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1993<\/year><\/dates><electronic-resource-num>10.1111\/j.1471-4159.1993.tb02173.x<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>18<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Determination of aniracetam and its main metabolite, N-anisoyl-GABA, in human plasma by high-performance liquid chromatography.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1990<\/year><\/dates><electronic-resource-num>10.1016\/s0378-4347(00)82342-7<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>19<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-\u03b2 Plaques in Alzheimer's Disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2024<\/year><\/dates><electronic-resource-num>10.3233\/jad-231247<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC11091568?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>20<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1997<\/year><\/dates><electronic-resource-num>10.1016\/s0091-3057(96)00133-5<\/electronic-resource-num><\/record>\n<\/records><\/xml>\n"

"\n\nMolGod<\/database>MOL-GOD<\/source-app>1<\/rec-number>17<\/ref-type><\/authors><\/contributors>AMPA receptor flip\/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1996<\/year><\/dates><electronic-resource-num>10.1523\/jneurosci.16-21-06634.1996<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.jneurosci.org\/content\/jneuro\/16\/21\/6634.full.pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>2<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1991<\/year><\/dates><electronic-resource-num>10.1073\/pnas.88.23.10936<\/electronic-resource-num><urls><related-urls><url>https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.88.23.10936<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>3<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2012<\/year><\/dates><electronic-resource-num>10.1111\/j.1755-5949.2010.00244.x<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/6493642<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>4<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Aniracetam does not alter cognitive and affective behavior in adult C57BL\/6J mice.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.1371\/journal.pone.0104443<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC4123976?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>5<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Oral aniracetam treatment in C57BL\/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2017<\/year><\/dates><electronic-resource-num>10.12688\/f1000research.11023.3<\/electronic-resource-num><urls><related-urls><url>https:\/\/f1000research.com\/articles\/6-1452\/v3\/pdf<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>6<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Spectrofluorimetric study on fluorescence quenching of tyrosine and l-tryptophan by the aniracetam cognition enhancer drug: quenching mechanism using Stern-Volmer and double-log plots.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2020<\/year><\/dates><electronic-resource-num>10.1002\/bio.3778<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>7<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Aniracetam does not improve working memory in neurologically healthy pigeons.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2019<\/year><\/dates><electronic-resource-num>10.1371\/journal.pone.0215612<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC6474613?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>8<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Designing a Formulation of the Nootropic Drug Aniracetam Using 2-Hydroxypropyl-\u03b2-Cyclodextrin Suitable for Parenteral Administration.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2018<\/year><\/dates><electronic-resource-num>10.3390\/pharmaceutics10040240<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC6320825?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>9<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1992<\/year><\/dates><electronic-resource-num>10.1002\/hipo.450020107<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>10<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Content determination of aniracetam in aniracetam inclusion complex by HPLC.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2009<\/year><\/dates><electronic-resource-num>10.1080\/10731190902908387<\/electronic-resource-num><urls><related-urls><url>https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10731190902908387?download=true<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>11<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Aniracetam attenuates H2O2-induced deficiency of neuron viability, mitochondria potential and hippocampal long-term potentiation of mice in vitro.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2006<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>12<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2003<\/year><\/dates><electronic-resource-num>10.1124\/mol.64.2.269<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>13<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>The hypoxia model in human psychopharmacology: neurophysiological and psychometric studies with aniracetam i.v.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1984<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>14<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Nakamura K<\/author><\/authors><\/contributors><titles><title>Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.<\/title><secondary-title>CNS drug reviews<\/secondary-title><\/titles><dates><year>2002<\/year><\/dates><electronic-resource-num>10.1111\/j.1527-3458.2002.tb00216.x<\/electronic-resource-num><urls><related-urls><url>https:\/\/onlinelibrary.wiley.com\/doi\/pdfdirect\/10.1111\/j.1527-3458.2002.tb00216.x<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>15<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>[3H]aniracetam binds to specific recognition sites in brain membranes.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1995<\/year><\/dates><electronic-resource-num>10.1046\/j.1471-4159.1995.65020912.x<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>16<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Development and validation of a liquid chromatographic method for the simultaneous determination of aniracetam and its related substances in the bulk drug and a tablet formulation.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2011<\/year><\/dates><electronic-resource-num>10.1016\/j.jpba.2011.06.005<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>17<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>et al.<\/author><\/authors><\/contributors><titles><title>Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1993<\/year><\/dates><electronic-resource-num>10.1111\/j.1471-4159.1993.tb02173.x<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>18<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Determination of aniracetam and its main metabolite, N-anisoyl-GABA, in human plasma by high-performance liquid chromatography.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1990<\/year><\/dates><electronic-resource-num>10.1016\/s0378-4347(00)82342-7<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>19<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-\u03b2 Plaques in Alzheimer's Disease.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>2024<\/year><\/dates><electronic-resource-num>10.3233\/jad-231247<\/electronic-resource-num><urls><related-urls><url>https:\/\/europepmc.org\/articles\/PMC11091568?pdf=render<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>20<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><\/authors><\/contributors><titles><title>Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions.<\/title><secondary-title><\/secondary-title><\/titles><dates><year>1997<\/year><\/dates><electronic-resource-num>10.1016\/s0091-3057(96)00133-5<\/electronic-resource-num><\/record>\n<\/records><\/xml>\n"